AEVA dropped 7.22% in a single session as a cluster of insider-selling filings hit simultaneously. CEO S. Salehian has already sold 41,083 shares and filed to sell an additional 300,000. A separate Form 144 filing discloses 450,000 RSUs queued in the pipeline. The combined overhang from these filings is substantial relative to AEVA's float, and the timing — all landing at once — amplified the day's sell-off.
The stock currently sits at $24.93, against an analyst consensus target of $25.13, leaving almost no gap between where the stock trades and where analysts think it belongs. That narrow spread gives the market little cushion to absorb selling pressure of this scale.
What it means
The ACCE score for AEVA stands at 41 out of 100. The breakdown tells a split story: Momentum scores 76 and Growth scores 64, but Value sits at just 10 and Quality at 13. That combination — strong top-line momentum, weak fundamentals — is exactly the profile that makes insider selling harder to dismiss.
Recibe el resumen semanal de ACCE
Rentabilidad de los índices, repaso de las selecciones y los mayores cambios de puntuación, cada domingo. Sin relleno.
On the growth side, year-over-year revenue is up 85.9%, which is a genuine headline number. The most recent earnings report (Q2 FY2026) came in with a beat of +0.1%, so the business is not in freefall operationally. But the quality metrics are a different picture. ROE stands at -516.1%, FCF yield is -7.1%, and net margin is not in positive territory. The market cap is $1.81B against a backdrop of negative free cash flow and deeply negative return on equity.
Insider selling is not automatically bearish — executives sell shares for many reasons. But three filings arriving together, covering a combined exposure of over 791,000 shares when you include the RSU pipeline, is a concentration of supply that the market is clearly pricing in real time. With the analyst target only $0.20 above the current price, there is no analyst-derived buffer to lean on.
This is a developing story. The RSU pipeline disclosed in the Form 144 has not yet translated into open-market sales, and the pace at which Salehian executes against the 300,000-share filing will matter. Watch for additional Form 4 filings in the coming sessions.
For the current price and full score breakdown, see acceinvestments.com/stocks/AEVA.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
